Evidence map›Paper›PMID 40128557›Full record

ArticleScientific reports2025

Characterization of pritumumab in murine models and primate safety study.

Avani A Mody, Rajesh Mukthavaram, Pengfei Jiang, Kishore Gangangari, Nagavarakishore Pillarsetty, Pranav R Kesari, Vijay Padul, Sneha L Kesari, Elnaz Rahbarlayegh, Mark C Glassy and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Avani A ModyCureScience Institute, San Diego, CA, USA.
Rajesh MukthavaramTranslational Neuro-Oncology Laboratory, University of California, San Diego, Moores Cancer Center, La Jolla, CA, USA.
Pengfei JiangTranslational Neuro-Oncology Laboratory, University of California, San Diego, Moores Cancer Center, La Jolla, CA, USA.
Kishore GangangariDepartment of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Nagavarakishore PillarsettyDepartment of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Pranav R KesariCureScience Institute, San Diego, CA, USA.
Vijay PadulRhenix Lifesciences, Hyderabad, India.
Sneha L KesariCureScience Institute, San Diego, CA, USA.
Elnaz RahbarlayeghSaint John's Health Center, Pacific Neurosciences Institute and Saint John's Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA, 90404, USA.
Mark C GlassyTranslational Neuro-Oncology Laboratory, University of California, San Diego, Moores Cancer Center, La Jolla, CA, USA.
Santosh KesariSaint John's Health Center, Pacific Neurosciences Institute and Saint John's Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA, 90404, USA. santosh.kesari@providence.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Pritumumab is a human IgG1 kappa antibody that targets ecto-domain vimentin (EDV) which is overexpressed in several malignant tumors including glioblastomas. To understand preclinical biological activity and safety of pritumumab derived from Chinese hamster ovary (CHO) cells, we evaluated tumor targeting ability, brain-tumor barrier permeability, growth inhibition, and primate safety studies. In-vivo and ex-vivo imaging studies demonstrate pritumumab to cross the blood brain/blood tumor barrier and an

Indexed as

Antibodies, MonoclonalBrain NeoplasmsGlioblastomaAnimalsAntibodies, Monoclonal, HumanizedBlood-Brain BarrierCell Line, TumorCHO CellsCricetinaeCricetulusDisease Models, AnimalFemaleHumansMacaca fascicularisMicePancreatic NeoplasmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedVimentinAnimal modelsBlood brain barrierImmunotherapyPritumumabVimentin

Identifiers

PMID40128557
PMCPMC11933471

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.